(S) -CR8

• Description :

  (S) -CR8 is the S-isomer of CR8. (S) -CR8 is a potent and selective CDK inhibitor with IC50s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S) -CR8 reduces SH-SY5Y cells survival (IC50 0.40 μM) [1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  CDK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/s-cr8.html

• Purity :

  99.0

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  CC[C@H](NC1=NC(NCC2=CC=C(C3=NC=CC=C3)C=C2)=C4N=CN(C(C)C)C4=N1)CO

• Molecular Formula :

  C24H29N7O

• Molecular Weight :

  431.53

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations :

  [1]K Bettayeb, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008 Oct 2;27 (44) :5797-807.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1084893-56-0]